Go Pro
TSE:MDNA

Medicenna Therapeutics Q4 2026 Earnings Report

Medicenna Therapeutics logo
C$0.41 -0.01 (-1.20%)
As of 08/21/2026 02:56 PM Eastern

Medicenna Therapeutics EPS Results

Actual EPS
-C$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Medicenna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicenna Therapeutics Announcement Details

Quarter
Q4 2026
Time
After Market Closes
Conference Call Date
Thursday, June 25, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Medicenna Therapeutics Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Medicenna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicenna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicenna Therapeutics and other key companies, straight to your email.

About Medicenna Therapeutics

Medicenna Therapeutics (TSE:MDNA) Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

View Medicenna Therapeutics Profile